文献速递眼底病与葡萄膜炎

抗血管内皮生长因子治疗糖尿病视网膜病变的经济激励警示

A Caveat About Financial Incentives for Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy.
PubMed 文献 · Am J Ophthalmol · 2022-07-25

本文为视角性文章,结合回顾性成本与利润分析,指出对非增殖性和增殖性糖尿病视网膜病变选择玻璃体腔抗血管内皮生长因子(VEGF)策略存在医生经济激励,可能给患者带来风险并增加医疗系统成本。基于DRCR Retina Network W和AB方案及PANORAMA试验数据,文章认为在功能结局等效时,医生应避免过度依赖抗VEGF注射,并警惕经济收益偏倚。

要点

  • 玻璃体腔阿柏西普策略治疗糖尿病玻璃体出血,较玻璃体切除联合激光利润增加76%,功能结局等效。
  • 非增殖性糖尿病视网膜病变预防性阿柏西普注射,较观察利润增加414%,每患者2年成本增加12,164至17,542美元,视觉功能无改善。
  • 作者认为医生应避免过度依赖抗VEGF注射,警惕经济收益偏倚。

核心结论

  • 抗VEGF治疗是增殖性糖尿病视网膜病变和糖尿病黄斑水肿的有用工具,但作者认为医生应避免在糖尿病视网膜病变治疗中过度依赖抗VEGF注射。
  • 视网膜专科医生应认识到抗VEGF单药治疗和预防性治疗的局限性、成本和风险,并在存在同等有效替代方案时避免偏向经济收益高的实践模式。

研究设计与样本

  • 视角性文章,结合回顾性成本与利润分析,综述并整合选定文献,采用活动成本法和时间成本法解读玻璃体腔阿柏西普策略治疗糖尿病视网膜病变的成本。
  • 使用DRCR Retina Network W和AB方案及PANORAMA试验的数据说明该治疗策略背后的潜在经济激励。

主要发现

  • 对糖尿病玻璃体出血采用玻璃体腔阿柏西普策略,较玻璃体切除联合激光利润增加76%,功能结局等效。
  • 对非增殖性糖尿病视网膜病变,预防性阿柏西普注射较观察利润增加414%,每患者2年成本增加12,164至17,542美元,视觉功能无改善。
  • 这些发现表明糖尿病视网膜病变管理中可能存在经济激励错位。

临床怎么用

  • 作者认为医生应避免在糖尿病视网膜病变治疗中过度依赖抗VEGF注射。
  • 作者认为视网膜专科医生应认识到抗VEGF单药治疗和预防性治疗的局限性、成本和风险,并在存在同等有效替代方案时避免偏向经济收益高的实践模式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To highlight the financial incentive to the physician of choosing an intravitreal anti-vascular endothelial growth factor (VEGF)-based strategy for treating non-proliferative and proliferative diabetic retinopathy, and its possible risks to the patient and costs to the health care system. DESIGN: Perspective with retrospective cost and profit analysis. METHODS: Review and synthesis of selected literature on the treatment of diabetic retinopathy, with interpretation of activity-based and time-based costing of an intravitreal aflibercept strategy for diabetic retinopathy. Data from the DRCR Retina Network Protocols W and AB and PANORAMA trial were used to illustrate the potential financial incentive underlying such a treatment strategy. RESULTS: Physician treatment algorithms for diabetic vitreous hemorrhage and non-proliferative diabetic retinopathy may be influenced by the substantial financial incentives that intravitreal aflibercept strategies present, despite functional equivalence with alternative and less profitable strategies. For example, pursuing an intravitreal aflibercept-based strategy for diabetic vitreous hemorrhage presents a 76% increased profit over pars plana vitrectomy with laser, with equivalent functional outcomes. For non-proliferative diabetic retinopathy, preventative aflibercept injections represent a potential 414% increase in profit over observation and an increased cost of $12,164 to $17,542 over 2 years per patient, with no improvement in visual function. These findings demonstrate that there may be misaligned financial incentives in the management of diabetic retinopathy. CONCLUSIONS: While anti-VEGF therapy is a useful tool in the management of proliferative diabetic retinopathy and diabetic macular edema, it is believed that physicians should avoid overreliance on anti-VEGF injections in the treatment of diabetic retinopathy. Retinal specialists should be cognizant of the limitations, costs, and risks of anti-VEGF monotherapy and prophylactic therapy, and of the imperative to avoid bias towards financially remunerative practice patterns when equally effective alternatives exist.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Young BK, Hwang M, Johnson MW, et al. A Caveat About Financial Incentives for Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy. Am J Ophthalmol. 2022. PMID: 35901996. doi:10.1016/j.ajo.2022.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。